Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anteriorly
Sponsor
EL Romany Ophthalmics Factory (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05699096
Collaborator
(none)
20
1
36
0.6
Study Details
Study Description
Brief Summary
Perfluorohexyloctaneis Essential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
20 participants
Observational Model:
Case-Only
Time Perspective:
Retrospective
Official Title:
Perfluorooctyl Bromideessential for Repositioning Giant Retinal Breaks and Can be Used for Removal of Subretinal Fluid as Well as Stabilization of the Retina to Offset
Anticipated Study Start Date
:
Jul 1, 2023
Anticipated Primary Completion Date
:
Jul 1, 2025
Anticipated Study Completion Date
:
Jul 1, 2026
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
eye surgery ,Vitreoretinal Surgery and Related Ocular Inflammation
|
Outcome Measures
Primary Outcome Measures
- flat the detached retina and displace the underneath fluids anteriorly [Base line]
the effect of Perfluorooctyl Bromide on the retina ,under ophthalmic microscope check the flatted retina
Eligibility Criteria
Criteria
Ages Eligible for Study:
20 Years
to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
-
- Is 20 years or older Has been diagnosed with Keratoconus; Has no other active ocular disease; Is not pregnant or nursing;
Exclusion Criteria:
- Is under the age of 20 Has best corrected visual acuity outside 20/400; Pregnant or nursing at the time of enrollment in the study;
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Girgis Boules | Cairo | Kubri EL Kubba | Egypt | 11711 |
Sponsors and Collaborators
- EL Romany Ophthalmics Factory
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
EL Romany Ophthalmics Factory
ClinicalTrials.gov Identifier:
NCT05699096
Other Study ID Numbers:
- ROPFO
First Posted:
Jan 26, 2023
Last Update Posted:
Jan 26, 2023
Last Verified:
Jan 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Additional relevant MeSH terms: